Hyper Corporation Inc. (KOSDAQ:065650)

Market Cap	46.14B +31.8%
Revenue (ttm)	80.77B +30.1%
Net Income	-3.04B
EPS	-369.03
Shares Out	10.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,873
Open	3,830.00
Previous Close	3,830.00
Day's Range	3,724.00 - 4,220.00
52-Week Range	3,200.00 - 14,500.00
Beta	1.51
Analysts	n/a
Price Target	n/a
Earnings Date	May 27, 2026

About Hyper Corporation

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and w...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 1997
• Employees: 44
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065650

Financial Performance

In 2025, Hyper Corporation's revenue was 76.19 billion, an increase of 32.04% compared to the previous year's 57.70 billion. Losses were -315.64 million, -99.61% less than in 2024.